Abstract

Solomon Sisay1 , Woldaregay Erku2 , Mulugeta Belay3 , Zufane Sisay2 , Moges Tiruneh4 , Desalegn Woldeyohannes5 *

Human immunodeficiency virus (HIV) infected person has greater frequency and severity of human papilloma virus (HPV)-associated cervical dysplasia than uninfected person. One of the risk factors for HPV infection and subsequent neoplasia of lower genital tract is impaired cell mediated immunity like in HIV patients. There is no clear information about infection of HPV and HIV in the same cell, but there is evidence which indicates role of HIV on HPV at molecular level. The impact of HPV on HIV is not also clearly understood. Currently, no data suggest that HPV acts differently in HIV positive person, but HPV persist in the lesion. Treatment for HPV in HIV patients involves both correction of immuno-suppression and combination of standard treatment use to clear HPV. HIV sero-positivity is known to be associated with an increased prevalence of ano-genital HPV infections in both sexes. Little is known whether HPV vaccine in HIV positive person can mount and maintain protective antibody titer against HPV infection. HIV positive women should undergo gynecological examination and vaccination against HPV genotypes to prevent the development of cervical cancer. The objective of this review is to indicate the interaction of HPV with HIV in modulating pathogenesis and disease progression in co-infected individuals.